CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BKRASG12SPredictiveSupportsResistanceLung CancerGefitinibEndoh et al., 2006
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2000
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanRowley et al., 2002
DKRASG12SPredictiveSupportsResistanceMultiple MyelomaMelphalanHoang et al., 2006
BIDH1R132CPredictiveSupportsSensitivity/ResponseBrain GliomaTemozolomideHouillier et al., 2010
DIDH1R132CPredictiveSupportsSensitivity/ResponseHigh Grade GliomaAGI-5198Rohle et al., 2013
BIDH1R132CPredictiveSupportsSensitivity/ResponseAcute Myeloid LeukemiaIvosidenib2015
CBRAFV600EPrognosticDoes Not SupportPoor OutcomeColorectal CancerHe et al., 2009
CKITT417_D419delinsYPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
DKITN822HPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DKITN822KPredictiveDoes Not SupportSensitivity/ResponseCancerImatinibHeinrich et al., 2003
DKITD816VPredictiveSupportsResistanceCancerImatinibHeinrich et al., 2003
DPDGFRAV561DPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DPDGFRAD842_H845DELDIMHPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DPDGFRAD842VPredictiveSupportsResistanceCancerImatinibHeinrich et al., 2003
DKITV560GPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DKITK642EPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
CKITExon 13 MutationPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
BKITExon 9 MutationPredictiveSupportsReduced SensitivityGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
CPDGFRAD842VPredictiveSupportsResistanceGastrointestinal Stromal TumorImatinibHeinrich et al., 2003
BKITEXPRESSIONPredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorImatinibHeinrich et al., 2008
DKITW557_K558delPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
DKITY503_F504insAYPredictiveDoes Not SupportResistanceCancerImatinibHeinrich et al., 2003
BBRAFV600KPredictiveSupportsSensitivity/ResponseMelanomaTrametinibFlaherty et al., 2012
DEGFRE746_A750delPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibCross et al., 2014
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaAfatinibLi et al., 2008
CEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibPao et al., 2004
DBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinib,Imatinib Mesylate,NilotinibBradeen et al., 2006
CBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 Y253FPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 D276GPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 D276GPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaNilotinibRedaelli et al., 2009
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
CBCR::ABL1Fusion AND ABL1 S417YPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibRedaelli et al., 2009
CBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibBranford et al., 2003
DBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaImatinibO'Hare et al., 2005
DATMD1930VPredictiveSupportsResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DATMK468FSPredictiveDoes Not SupportResistanceChronic Lymphocytic LeukemiaDoxorubicinNavrkalova et al., 2013
DBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinib,Imatinib MesylateBradeen et al., 2006
DBCR::ABL1Fusion AND ABL1 E292VPredictiveSupportsResistanceChronic Myeloid LeukemiaNilotinibBradeen et al., 2006
Page 75 of 96
PreviousNext